Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common blood thinner shield psoriasis Patients' arteries?

NCT ID NCT07744191

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This trial tests whether antiplatelet medications, specifically clopidogrel and aspirin, can reduce inflammation in the blood vessels of people with psoriasis or psoriatic arthritis. Participants take each drug or a placebo for four weeks, and researchers measure changes in inflammatory markers from blood vessel cells. The goal is to see if these drugs might lower the risk of atherosclerosis, a condition linked to heart disease, in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aspirin and clopidogrel
What this could lead to
If clopidogrel reduces blood vessel inflammation, it could point toward a way to lower heart disease risk in people with psoriasis.
What could go wrong
This is a small, early-stage trial measuring biological markers, not actual heart events. The effect may be modest or not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. One of the following: 1. A history of psoriasis as confirmed by a board-certified dermatologist OR 2. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist 2. Age ≥ 18 \& \< 90 years 3. Able and willing to provide written informed consent for the study 4. English-speaking unless a translated informed consent form is approved 5. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment Exclusion Criteria: 1. A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease 2. Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment 3. Uncontrolled hypertension resting systolic blood pressure \> 180 mm Hg or diabetes HbA1c \> 10% 4. Known active cancer receiving treatment 5. Pregnancy 6. Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600) 7. A history of severe bleeding or bleeding disorders 8. Active gastrointestinal ulcer 9. Active pathological bleeding. 10. Chronic kidney disease (CrCl \< 30ml/min) 11. Congestive heart failure 12. Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules 13. History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs 14. Currently breastfeeding 15. Persons of childbearing potential unwilling to use acceptable contraception during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis (PSO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis (PSO) Psoriatic arthritis (PSA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.